Data from HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care
Alessandra Fabi(Agostino Gemelli University Polyclinic), Marcella Mottolese, Letizia Perracchio, Franco Di Filippo, Giulio Metro(University of Perugia), Cecilia Nisticò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Francesco Cognetti(Apple (Israel)), G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), Isabella Sperduti(San Gallicano Hospital), Cristiana Ercolani, Anna Di Benedetto, Simonetta Buglioni, Paola Papaldo(Cancer Institute (WIA)), Elisa Melucci
Cited by 0
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
|JAMA Oncology|2018|345
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
|Journal of Clinical Oncology|2015|253
Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma
|Journal of Clinical Oncology|2020|226